Anixa Biosciences Covid-19 therapy demonstrated comparable potency to remdesivir in pre-clinical testing
On Dec. 14, 2020, Anixa Biosciences announced that it and partner OntoChem GmbH had verified that one of their recently discovered compounds is similar in potency to remdesivir, the only approved anti-viral drug against SARS-Cov-2.
The companies previously identified multiple compounds that could disrupt the function of a viral enzyme called an endoribonuclease (also known as Non-Structural Protein-15, or NSP-15).
Tags:
Source: Anixa Biosciences
Credit: Photo: Scanning electron microscope shows SARS-CoV-2 emerging from the surface of cells cultured in the lab. Courtesy: Rocky Mountain Laboratory,
